^
Association details:
| Biomarker: | KIT exon 17 mutation + KIT exon 18 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
Excerpt:
...- Histologic diagnosis of GIST with presence of KIT exon 17, 18, or 14 mutation, or SDHB deficiency on tumor biopsy and/ or liquid biopsy....
Trial ID:
Source:
Title:
Regorafenib third-lined therapy in advanced GISTs: A single center analysis based on different genotypes.
Published date:
05/26/2022
Excerpt:
...a total of 62 patients with advanced GIST refractory to imatinib and/or sunitinib were enrolled in this study....In terms of secondary mutations, patients with activation loop mutations (exon 17+18) showed both longer mPFS (7.3 months vs 1.9 months, P= 0.001) and longer mOS (20.3 months vs 7.7 months, P= 0.059) than those patients with non-activation loop mutations....Regorafenib seems to have better treatment efficacy in GIST patients with SDH deficiency compared to those with primary KIT mutations, and better with secondary mutations in activation loop than those with non-activation loop mutations.
DOI:
10.1200/JCO.2022.40.16_suppl.11537
